Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Theriva Biologics, Inc. (SFPH) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Theriva Biologics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 894158.
Total stock buying since 2014: $3,218,884.
Total stock sales since 2014: $98,836.
Total stock option exercises since 2014: $21,564.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 140,000 | $116,284 | 0 | $0 | 0 | $0 |
| 2022 | 100,000 | $43,700 | 0 | $0 | 0 | $0 |
| 2021 | 50,000 | $24,600 | 0 | $0 | 0 | $0 |
| 2019 | 50,000 | $20,800 | 150,565 | $98,836 | 0 | $0 |
| 2017 | 0 | $0 | 0 | $0 | 228,773 | $20,589 |
| 2015 | 937,500 | $3,000,000 | 0 | $0 | 10,842 | $975 |
| 2014 | 10,000 | $13,500 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-06 | 40,000 | $26,160 | 0 | $0 | 0 | $0 |
| 2023-02 | 50,000 | $49,599 | 0 | $0 | 0 | $0 |
| 2023-01 | 50,000 | $40,525 | 0 | $0 | 0 | $0 |
| 2022-12 | 100,000 | $43,700 | 0 | $0 | 0 | $0 |
| 2021-05 | 50,000 | $24,600 | 0 | $0 | 0 | $0 |
| 2019-08 | 50,000 | $20,800 | 0 | $0 | 0 | $0 |
| 2019-04 | 0 | $0 | 150,565 | $98,836 | 0 | $0 |
| 2017-03 | 0 | $0 | 0 | $0 | 228,773 | $20,589 |
| 2015-09 | 937,500 | $3,000,000 | 0 | $0 | 0 | $0 |
| 2015-04 | 0 | $0 | 0 | $0 | 10,842 | $975 |
| 2014-05 | 10,000 | $13,500 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-06-07 | Shallcross Steven A (CEO and CFO) | Buy | 14,000 | .69 | 9,702 |
| 2023-06-06 | Shallcross Steven A (CEO and CFO) | Buy | 26,000 | .63 | 16,458 |
| 2023-02-10 | Shallcross Steven A (CEO and CFO) | Buy | 25,000 | 1.04 | 26,074 |
| 2023-02-02 | Shallcross Steven A (CEO and CFO) | Buy | 25,000 | .94 | 23,525 |
| 2023-01-25 | Shallcross Steven A (CEO and CFO) | Buy | 25,000 | .87 | 21,825 |
| 2023-01-20 | Shallcross Steven A (CEO and CFO) | Buy | 25,000 | .75 | 18,700 |
| 2022-12-29 | Shallcross Steven A (CEO and CFO) | Buy | 100,000 | .44 | 43,700 |
| 2021-05-10 | Shallcross Steven A (CEO and CFO) | Buy | 50,000 | .49 | 24,600 |
| 2019-08-23 | Shallcross Steven A (CEO and CFO) | Buy | 50,000 | .42 | 20,800 |
| 2019-04-03 | Intrexon Corp | Sale | 95,241 | .65 | 61,906 |
| 2019-04-02 | Intrexon Corp | Sale | 13,646 | .66 | 9,006 |
| 2019-04-01 | Intrexon Corp | Sale | 41,678 | .67 | 27,924 |
| 2017-03-14 | Kraws Jeffrey J | Option Ex | 228,773 | .09 | 20,589 |
| 2015-09-02 | Intrexon Corp | Buy | 937,500 | 3.20 | 3,000,000 |
| 2015-04-01 | Wolf Jeffrey Alan | Option Ex | 10,842 | .09 | 975 |
| 2014-05-22 | Ballantyne Charles Evan (Chief Financial Officer) | Buy | 10,000 | 1.35 | 13,500 |
Insider trading activities including stock purchases, stock sales, and option exercises of SFPH listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Theriva Biologics, Inc. (symbol SFPH, CIK number 894158) see the Securities and Exchange Commission (SEC) website.